Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome
暂无分享,去创建一个
N. McDonnell | H. Tae | M. Talan | T. Cooper | W. Briest | M. Krawczyk
[1] H. Dietz,et al. The Haploinsufficient Col3a1 Mouse as a Model for Vascular Ehlers-Danlos Syndrome , 2010, Veterinary pathology.
[2] B. Brooke. Celiprolol therapy for vascular Ehlers-Danlos syndrome , 2010, The Lancet.
[3] C. van Breemen,et al. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. , 2010, The Journal of thoracic and cardiovascular surgery.
[4] S. Laurent,et al. Effect of Celiprolol on Prevention of Cardiovascular Events in Vascular Ehlers-Danlos Syndrome , 2009 .
[5] P. Byers,et al. Successful endovascular repair of acute type B aortic dissection in undiagnosed Ehlers-Danlos syndrome type IV. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[6] A. Fleischer,et al. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. , 2009, Journal of drugs in dermatology : JDD.
[7] J. H. van Bockel,et al. Clinical Trial of Doxycycline for Matrix Metalloproteinase-9 Inhibition in Patients With an Abdominal Aneurysm: Doxycycline Selectively Depletes Aortic Wall Neutrophils and Cytotoxic T Cells , 2009, Circulation.
[8] B. Rubin,et al. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. , 2008, Journal of vascular surgery.
[9] J. Schlessinger,et al. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. , 2008, Journal of drugs in dermatology : JDD.
[10] M. Radomski,et al. Long-Term Doxycycline Is More Effective Than Atenolol to Prevent Thoracic Aortic Aneurysm in Marfan Syndrome Through the Inhibition of Matrix Metalloproteinase-2 and -9 , 2008, Circulation research.
[11] C. McCulloch,et al. Feasibility of Minocycline and Doxycycline Use as Potential Vasculostatic Therapy for Brain Vascular Malformations: Pilot Study of Adverse Events and Tolerance , 2008, Cerebrovascular Diseases.
[12] D. Germain,et al. Orphanet Journal of Rare Diseases BioMed Central Review Ehlers-Danlos syndrome type IV , 2007 .
[13] M. Rendon,et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. , 2007, Journal of the American Academy of Dermatology.
[14] T. Katagiri,et al. OJ-032 Measurement of the Left Atrial Isthmus and Obstacles(Arrhythmia, therapy-05, The 71st Annual Scientific Meeting of the Japanese Circulation Society) , 2007 .
[15] Y. Fukushima,et al. Genetic aspects of the vascular type of Ehlers-Danlos syndrome (vEDS, EDSIV) in Japan. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[16] M. Lohse,et al. Interstitial remodeling in β1-adrenergic receptor transgenic mice , 2006, Basic Research in Cardiology.
[17] L. Golub,et al. Clinical and Biochemical Results of the Metalloproteinase Inhibition with Subantimicrobial Doses of Doxycycline to Prevent Acute Coronary Syndromes (MIDAS) Pilot Trial , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[18] C. Liapis,et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms , 2004, Current medical research and opinion.
[19] J. Bikowski. Subantimicrobial dose doxycycline for acne and rosacea. , 2003, Skinmed.
[20] P. Sastry. Matrix metalloproteinase inhibitor therapy to prevent complications as well as therapy for Ehler-Danlos syndrome. , 2002, Medical hypotheses.
[21] R. Strasser,et al. Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-neuronal but PKC-dependent pathway. , 2002, Cardiovascular research.
[22] B. Baxter,et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. , 2002, Journal of vascular surgery.
[23] B. Baxter,et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. , 2002, Journal of vascular surgery.
[24] P. Byers,et al. Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. , 2001, American journal of human genetics.
[25] M. Leinonen,et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. , 2001, Journal of vascular surgery.
[26] H. Newman,et al. Utilisation of locally delivered doxycycline in non-surgical treatment of chronic periodontitis. A comparative multi-centre trial of 2 treatment approaches. , 2001, Journal of clinical periodontology.
[27] H. Baba,et al. Cardiac remodeling after long term norepinephrine treatment in rats. , 2001, Cardiovascular research.
[28] T. Noma,et al. Enhanced Expression of Matrix Metalloproteinase-9 in Abdominal Aortic Aneurysms , 2001, World Journal of Surgery.
[29] M. Thompson,et al. Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. , 2000, Journal of vascular surgery.
[30] B. Rubin,et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. , 2000, Journal of vascular surgery.
[31] B. Baxter,et al. MMP Inhibition in Abdominal Aortic Aneurysms: Rationale for a Prospective Randomized Clinical Trial , 1999, Annals of the New York Academy of Sciences.
[32] R. Jaenisch,et al. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[33] P. Byers,et al. Mutations in the COL3A1 gene result in the Ehlers-Danlos syndrome type IV and alterations in the size and distribution of the major collagen fibrils of the dermis. , 1997, The Journal of investigative dermatology.
[34] R. Mecham,et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. , 1995, The Journal of clinical investigation.
[35] V. McKusick,et al. Patients with Ehlers-Danlos syndrome type IV lack type III collagen. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Das,et al. Ehlers-Danlos Syndrome , 2022, Neurocutaneous Disorders.
[37] T. Shimada,et al. Vascular type of Ehlers-Danlos syndrome. , 2008, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[38] B. Baxter,et al. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. , 2008, Journal of vascular surgery.
[39] B. Sloan,et al. The use and safety of doxycycline hyclate and other second-generation tetracyclines. , 2008, Expert opinion on drug safety.
[40] Jorge Sánchez,et al. Safety and efficacy of doxycycline in the treatment of rosacea , 2022 .
[41] Eter,et al. CLINICAL AND GENETIC FEATURES OF EHLERS – DANLOS SYNDROME TYPE IV , THE VASCULAR TYPE , 2022 .